Cytostatic Activity of Sanguinarine and a Cyanide Derivative in Human Erythroleukemia Cells Is Mediated by Suppression of c-MET/MAPK Signaling

• Main Authors: Deng, L. (Author), Fan, Y. (Author), Hao, X. (Author), Li, J. (Author), Mu, S. (Author), Tang, Y. (Author), Xu, X. (Author), Zhong, T. (Author)
• Format: Article
• Language: English
• Published: MDPI 2023
• Subjects: c-MET; leukemia; MAPK; PI3K/mTOR; sanguinarine; STAT3
• Online Access: View Fulltext in Publisher; View in Scopus

 Sanguinarine (1) is a natural product with significant pharmacological effects. However, the application of sanguinarine has been limited due to its toxic side effects and a lack of clarity regarding its molecular mechanisms. To reduce the toxic side effects of sanguinarine, its cyanide derivative (1a) was first designed and synthesized in our previous research. In this study, we confirmed that 1a presents lower toxicity than sanguinarine but shows comparable anti-leukemia activity. Further biological studies using RNA-seq, lentiviral transfection, Western blotting, and flow cytometry analysis first revealed that both compounds 1 and 1a inhibited the proliferation and induced the apoptosis of leukemic cells by regulating the transcription of c-MET and then suppressing downstream pathways, including the MAPK, PI3K/AKT and JAK/STAT pathways. Collectively, the data indicate that 1a, as a potential anti-leukemia lead compound regulating c-MET transcription, exhibits better safety than 1 while maintaining cytostatic activity through the same mechanism as 1. © 2023 by the authors.